Peter Thiel-backed Canadian biotech developer AbCellera Biologics said on Monday that it expects to raise up to $391 million in its initial public offering. The company will issue 23 million shares for $14-17 apiece. The shares will be listed on Nasdaq under the symbol ABCL.
